Physician profile
Laura E Hamilton
NPI 1205928538
$4,404.54
in general payments reported to CMS, 2019-2025
35 companies · $535 in 2025
The $535 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $830 · 2021: $1,184 · 2022: $538 · 2023: $430 · 2024: $317 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $960.78 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $763.81 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $362.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $327.35 | 2019-2024 | Shingrix |
| Abbvie INC. | $315.31 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.39 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $205.60 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $141.55 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $125.88 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.49 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.45 | 2020-2021 | |
| Mannkind Corporation | $76.74 | 2019-2020 | |
| Daiichi Sankyo INC. | $60.54 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $50.55 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $49.83 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.19 | 2020 | |
| Ani Pharmaceuticals, INC. | $47.71 | 2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $43.70 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $36.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $31.04 | 2022 | |
| Nestle Healthcare Nutrition INC. | $28.60 | 2021 | |
| Arbor Pharmaceuticals, INC. | $28.45 | 2021 | |
| Amarin Pharma, INC. | $25.69 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $23.60 | 2021 | |
| Phadia US INC. | $23.44 | 2022 | |
| Bardy Diagnostics, INC. | $23.19 | 2021 | |
| Biogen, INC. | $23.01 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.55 | 2022 | |
| Axsome Therapeutics, INC. | $18.06 | 2024 | Auvelity |
| Astellas Pharma US INC | $16.65 | 2019 | |
| Corcept Therapeutics | $16.12 | 2025 | Korlym |
| Radius Health, INC. | $13.88 | 2019 | |
| Genentech USA, INC. | $13.73 | 2020 | |
| Amgen INC. | $13.60 | 2025 | Repatha, Otezla |
| Zyla Life Sciences, INC. | $13.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.